Last update Nov. 9, 2024

Disopyramide

Compatible

Safe product and/or breastfeeding is the best option.

Disopyramide is a class Ia antiarrhythmic with an action on the heart similar to that of quinidine. It also has antimuscarinic properties. It is used in the treatment of supraventricular and ventricular arrhythmias. Oral or intravenous administration.

It is excreted in breast milk in a clinically insignificant amount (Wakaumi 2005, Ellsworth 1989, Hoppu 1986, MacKintosh 1985, Barnett 1982) and no problems have been observed in infants born to mothers treated with this drug. (Ellsworth 1989, Hoppu 1986, MacKintosh 1985, Barnett 1982 )

Plasma levels in these infants were very low or below the limit of detection.  (Hoppu 1986, MacKintosh 1985, Barnett 1982)

Because of its antimuscarinic action, it may interfere with milk production in the first 4 to 6 weeks after delivery.

American Academy of Pediatrics: medication generally compatible with breast-feeding. (AAP 2001)

 

 

....

Alternatives

We do not have alternatives for Disopyramide since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Disopyramide in other languages or writings:

Group

Disopyramide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Disopyramide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 - 83 %
Molecular weight 340 daltons
Protein Binding 50 - 65 %
pKa 16.19 -
Tmax 2.3 (0.5 - 3) hours
T½ 6.7 (4 - 10) hours
M/P ratio 0.4 - 0.9 -
Theoretical Dose 0.2 - 0.86 mg/Kg/d
Relative Dose 1.3 - 8.6 %
Ped.Relat.Dose 2.3 - 7 %

References

  1. Wakaumi M, Tsuruoka S, Sakamoto K, Shiga T, Fujimura A. Pilsicainide in breast milk from a mother: comparison with disopyramide and propafenone. Br J Clin Pharmacol. 2005 Jan;59(1):120-2. No abstract available. Abstract Full text (link to original source) Full text (in our servers)
  2. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  3. Ellsworth AJ, Horn JR, Raisys VA, Miyagawa LA, Bell JL. Disopyramide and N-monodesalkyl disopyramide in serum and breast milk. DICP. 1989 Jan;23(1):56-7. Abstract
  4. Hoppu K, Neuvonen PJ, Korte T. Disopyramide and breast feeding. Br J Clin Pharmacol. 1986 May;21(5):553. No abstract available. Abstract Full text (link to original source)
  5. MacKintosh D, Buchanan N. Excretion of disopyramide in human breast milk. Br J Clin Pharmacol. 1985 Jun;19(6):856-7. No abstract available. Abstract Full text (link to original source)
  6. Barnett DB, Hudson SA, McBurney A. Disopyramide and its N-monodesalkyl metabolite in breast milk. Br J Clin Pharmacol. 1982 Aug;14(2):310-2. Abstract Full text (link to original source)

Total visits

5,306

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM